Source comparison
Oral Precursors: NMN vs NR
Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors — molecules the body converts into NAD+ through natural pathways. Conversion path NMN → NAD+ (via NMNAT enzymes) NR → NMN → NAD+ (extra step) Typical dose 300-600 mg/day
This comparison does not assign a generated winner or score.
- Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors — molecules the body converts into NAD+ through natural pathways.
- Conversion path
- NMN → NAD+ (via NMNAT enzymes)
- NR → NMN → NAD+ (extra step)
- Typical dose
- 300-600 mg/day
- 500-1000 mg/day
- Timeline
- 2-4 weeks to see effects
- Research base
- Growing (newer)
- Larger (more clinical trials)
- U.S. status evolving
- FDA GRAS approved
- Important note: No head-to-head human trial comparing NR vs NMN exists. Both can raise NAD+ biology. The "fewer steps" argument for NMN is simplified — absorption, digestion, conversion to NR or nicotinamide, and tissue uptake matter as much as the diagram on a label.
- Tissue preferences:
- Muscle
- NR
- High NRK2 enzyme expression
- Liver
- NMN
- High Slc12a8 transporter expression
- Brain
- Unclear
- May rely on NAM crossing blood-brain barrier
- Small intestine
- 100-fold higher Slc12a8 vs brain
- What oral supplements show in the data:
- Gradual NAD+ elevation (not immediate)
- Effects typically plateau at 600mg NMN or 1000mg NR — higher doses don’t seem to help more
- Adverse events are limited to mild GI upset at high doses
- Effects plateau at 4-8 weeks (suggesting tissue saturation)